As myloral and other their other antigen feeding approaches have had ZERO side effects, FDA approval really is pretty much a foregone conclusion IF the trials were properly run AND the results are statistically significant.
Statistically significant results, even if modest, will pave the way for Myloral to become standard-of-care treatment--either alone, or, more likely, IN COMBINATION with other treatments. Myloral, if approved, would be the best candidate for combination therapy because its mechanism of action is complimentary to all existing modalities.
As to your suggestion that my approach is a crap shot, you're mistaken, "IMHO." I have definately done my homework here, and, unlike the come-out roll in craps, the odds are not against me. More importantly, my approach is investing, leveraged investment. If this works, you can be sure that I will want to stay on board for the long haul. The put is just a hedge, albeit a potentially profitibale one. |
